Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735657 | 0.91 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3830424 | 0.91 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7122592 | 0.91 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7469413 | 0.83 | PKM (0.72) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14470279 | 0.83 | ALDH1A1 (0.75) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6805741 | 0.83 | ALDH1A1 (0.81) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1988224 | 0.83 | ALDH1A1 (0.81) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6744239 | 0.82 | ALDH1A1 (0.71) | POLBPKMALDH1A1LMNAGAA | |
| SCHEMBL24600469 | 0.82 | POLB (0.62) | POLBPKMALDH1A1LMNAAPOBEC3A | |
| SCHEMBL20198535 | 0.82 | POLB (0.67) | POLBPKMALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | POLB 4871/4885PKM 4311/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.